Managing Complexity: Standardizing Workflows for Multiple Bispecific Therapies

Experts discuss how institutions can develop standardized operational workflows that accommodate multiple bispecific products with different administration requirements, particularly as more products become available.

EP: 1.Expanding Horizons: The Present and Future of Bispecific Antibodies Across Oncology

EP: 2.Revolutionizing Cancer Treatment: Key Bispecific Antibody Approvals

EP: 3.How Bispecific Antibodies Are Reshaping Cancer Care

EP: 4.Optimizing Bispecific Antibody Use: Opportunities to Broaden Patient Access

EP: 5.Integrating Bispecific Antibodies in Community Oncology: Benefits and Considerations

EP: 6.Overcoming Key Operational Challenges in Integrating Bispecific Therapies

EP: 7.Partnerships in Bispecific Therapy: A Model for Supporting Community Oncology

Now Viewing

EP: 8.Managing Complexity: Standardizing Workflows for Multiple Bispecific Therapies

Video content above is prompted by the following:

How can institutions develop standardized operational workflows that accommodate multiple bispecific products with different administration requirements, particularly as more products become available?

Related Videos

Related Content

Advertisement

March 26th 2025

Speech Recognition Tools May Boost Clinician Documentation Efficiency

Brooke McCormick

Documentation efficiency was higher among younger and male clinicians.

December 23rd 2024

Five Years Later: Ongoing COVID-19 Challenges, Next Steps

Brooke McCormick

On this episode of Managed Care Cast, we speak with Jenny Han, MD, of Emory School of Medicine and Grady Hospital, about COVID-19, long COVID, and strategies for prevention and care.

March 26th 2025

FDA Approves Cabozantinib for Advanced Pancreatic Neuroendocrine Tumors

Giuliana Grossi

With strong progression-free survival benefits demonstrated in the CABINET trial and updates to National Comprehensive Cancer Network guidelines, this approval reinforces cabozantinib’s role in improving outcomes for patients facing these challenging cancers.

December 17th 2024

Diving Into Patient Preferences for Blood Cancer Treatments With Dr Sikander Ailawadhi

Three abstracts presented at the 2024 American Society of Hematology annual meeting focused on patient preferences and treatment choices in blood cancers.

March 25th 2025

FDA Approves First New Class of Oral Antibiotics for Uncomplicated UTIs in Nearly 30 Years

Brooke McCormick

The approval of gepotidacin (Blujepa; GSK) introduces the first new class of oral antibiotics for uncomplicated urinary tract infections (UTIs) in nearly 30 years.

March 25th 2025

Ocular Adverse Events From Mirvetuximab Soravtansine Not Associated With HRQoL Impact in FRα+ Ovarian Cancer

Brooke McCormick

New phase 3 data provide reassurance on safety, tolerability, and overall benefit-risk of mirvetuximab soravtansine (Elahere) for patients with folate receptor alpha-positive (FRα+), platinum-resistant ovarian cancer.

Related Content

Advertisement

March 26th 2025

Speech Recognition Tools May Boost Clinician Documentation Efficiency

Brooke McCormick

Documentation efficiency was higher among younger and male clinicians.

December 23rd 2024

Five Years Later: Ongoing COVID-19 Challenges, Next Steps

Brooke McCormick

On this episode of Managed Care Cast, we speak with Jenny Han, MD, of Emory School of Medicine and Grady Hospital, about COVID-19, long COVID, and strategies for prevention and care.

March 26th 2025

FDA Approves Cabozantinib for Advanced Pancreatic Neuroendocrine Tumors

Giuliana Grossi

With strong progression-free survival benefits demonstrated in the CABINET trial and updates to National Comprehensive Cancer Network guidelines, this approval reinforces cabozantinib’s role in improving outcomes for patients facing these challenging cancers.

December 17th 2024

Diving Into Patient Preferences for Blood Cancer Treatments With Dr Sikander Ailawadhi

Three abstracts presented at the 2024 American Society of Hematology annual meeting focused on patient preferences and treatment choices in blood cancers.

March 25th 2025

FDA Approves First New Class of Oral Antibiotics for Uncomplicated UTIs in Nearly 30 Years

Brooke McCormick

The approval of gepotidacin (Blujepa; GSK) introduces the first new class of oral antibiotics for uncomplicated urinary tract infections (UTIs) in nearly 30 years.

March 25th 2025

Ocular Adverse Events From Mirvetuximab Soravtansine Not Associated With HRQoL Impact in FRα+ Ovarian Cancer

Brooke McCormick

New phase 3 data provide reassurance on safety, tolerability, and overall benefit-risk of mirvetuximab soravtansine (Elahere) for patients with folate receptor alpha-positive (FRα+), platinum-resistant ovarian cancer.